18702 N. Creek Parkway
Suite 100
Bothell, WA 98011
United States
610-321-3700
https://immunome.com
Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 55
Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
---|---|---|---|---|
Dr. Clay B. Siegall Ph.D. | President, CEO & Chairman | 1,43M | N/D | 1961 |
Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
L'ISS Governance QualityScore di Immunome, Inc. al 1 maggio 2024 è 10. I criteri di valutazione fondamentali sono revisione: 10; Consiglio di Amministrazione: 10; diritti degli azionisti: 7; retribuzione: 8.